This cohort study evaluates whether there is an association between sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and risk of serious liver events among patients with cirrhosis who are being treated with furosemide and spironolactone. This evidence concerns the gene SLC5A2 and Cirrhosis.